Skip to main
DMAC

DMAC Earnings Dates & Reports

DMAC Most Recent Earnings

Report Date
Period EndingQ4 2025
Est. EPS-$0.18
Actual EPS-$0.17
EarningsBeat

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

DMAC Earnings per Share (EPS) History

Signup for full access
Browse free

DMAC Latest Earnings

The value each DMAC share was expected to gain vs. the value each share gained.

DMAC reported its most recent earnings on for Q4 2025, posting earnings per share (EPS) of -$0.17. This exceeded analysts' expectations of -$0.18 by 5.56%, marking a Beat.

For comparison, DiaMedica Therapeutics Inc reported EPS of -$0.18 in the same quarter last year.

The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$0.18.

DMAC Earnings History

Earnings
Est. EPSActual EPSSurprise
Q1 2026
-$0.18
Q4 2025
-$0.18-$0.17-5.56%
Q3 2025
-$0.16-$0.17+6.25%
Q2 2025
-$0.19-$0.18-5.26%
Q1 2025
-$0.18-$0.180.00%
View all

DMAC Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the DiaMedica Therapeutics Inc’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange

DMAC Earnings FAQs

DMAC last reported earnings on Mar 31, 2026 for Q4 2025, posting an EPS of -$0.17, which Beat the estimate of -$0.18 by 5.56%.

For Q4 2025, DMAC reported an EPS of -$0.17, exceeding analysts' estimate of -$0.18 by 5.56%.

For Q4 2025, DMAC Beat expectations with an actual EPS of -$0.17 vs. an estimated EPS of -$0.18.

Following the last earnings report on Mar 31, 2026, DMAC's stock price moved — from — to —.

The next DMAC earnings call is scheduled for May. 12, 2026, where executives will discuss financial results and outlook.

DiaMedica Therapeutics Inc (DMAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.